Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Clearmind MedicineFRA:CWY0 22 Debt-to-Equity is 0.14 as of Jul. 2026, which is 600% above its 10-year median of 0.02. GuruFocus rates FRA:CWY0 with a GF Score™ of 22/100. The stock has 2 warning signs investors should review. Among 964 Biotechnology companies, Clearmind Medicine ranks better than 52.49% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Clearmind Medicine's Debt-to-Equity or its related term are showing as below:
FRA:CWY0'
s Debt-to-Equity Range Over the Past 10 Years
Min: -0.03 Med: 0.02 Max: 1.49
Current: 0.14
During the past 9 years, the highest Debt-to-Equity Ratio of Clearmind Medicine was 1.49. The lowest was -0.03. And the median was 0.02.
FRA:CWY0's Debt-to-Equity is ranked better than 52.49% of 964
companies
in the Biotechnology industry
Industry Median: 0.155
vs FRA:CWY0: 0.14
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Clearmind Medicine Debt-to-Equity Related Terms
Clearmind Medicine Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Clearmind Medicine's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:CWY0 vs CASIF, BIXT, ACUT: Debt-to-Equity Comparison
For the Biotechnology subindustry, Clearmind Medicine's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Clearmind Medicine Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Clearmind Medicine's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Clearmind Medicine's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Clearmind Medicine (FRA:CWY0) has a Debt-to-Equity of 0.14 as of Jul. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Clearmind Medicine and its competitors. This is 600% above median its historical median of 0.02. According to the industry distribution chart, Clearmind Medicine ranks #458 out of 964 companies in the Biotechnology industry, placing it in the top 47.5%.
Is Clearmind Medicine's Debt-to-Equity too high?
Clearmind Medicine's current Debt-to-Equity of 0.14 is 600% above median its 10-year median of 0.02. The Biotechnology industry median Debt-to-Equity is 0.16. Clearmind Medicine's value of 0.14 is 9.7% below this industry median. Based on the distribution chart, Clearmind Medicine ranks #458 out of 964 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Clearmind Medicine has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Clearmind Medicine's Debt-to-Equity compare to CASIF and BIXT?
According to the Biotechnology industry distribution chart, Clearmind Medicine ranks #458 out of 964 companies for Debt-to-Equity. This puts Clearmind Medicine in the upper half of its industry. The industry median Debt-to-Equity is 0.16. Clearmind Medicine's value of 0.14 is 9.7% below this benchmark. While the company's 10-year median is 0.02 vs. the industry median of 0.16, Clearmind Medicine has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 964 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Clearmind Medicine's current Debt-to-Equity of 0.14 is 9.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Clearmind Medicine and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Clearmind Medicine's current Debt-to-Equity is 0.14, which is 600% above median its own 10-year median of 0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clearmind Medicine stock overvalued right now?
Clearmind Medicine (FRA:CWY0) has a current Debt-to-Equity of 0.14. The current Debt-to-Equity is 0.14, which is 600% above median its 10-year median of 0.02 and 9.7% below the Biotechnology industry median of 0.16. Clearmind Medicine's overall GF Score™ is 22/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Clearmind Medicine (FRA:CWY0), the current Debt-to-Equity is 0.14 as of Jul. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Clearmind Medicine Inc is a clinical-stage pharmaceutical company engaged in Phase I/IIa clinical trials of novel psychedelic medicines. The Company focuses on developing treatments for mental health disorders, including alcohol use disorder (AUD), binge drinking, and eating disorders. Its activities are centered on the research and development of 5-methoxy-2-aminoindane (MEAI). It operates through a single research and development segment, which is conducted in Israel.
22GF Score
Get the complete analysis for FRA:CWY0
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:CWY0 has been successfully added to your 
